PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients
- 5 January 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 162 (1), 19-30
- https://doi.org/10.1007/s10549-016-4095-2
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Prognostic significance of PD-L1 and PD-L2 in breast cancerHuman Pathology, 2015
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasHuman Pathology, 2015
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancerOncotarget, 2015
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerScientific Reports, 2015
- Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast CancerClinical Breast Cancer, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2010